Adult Malignant Glioma Therapeutics Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Adult Malignant Glioma Therapeutics Market Size Likely To Evolve From 2025 Through 2034?

The market size for adult malignant glioma therapeutics has undergone rapid growth in recent years. It is anticipated to expand from $2.25 billion in 2024 to $2.47 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.1%. The historical growth witnessed in this period can be ascribed to factors such as elevated incidence rates, patient advocacy efforts, and the evolution of personalized medicine approaches.

The adult malignant glioma therapeutics market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $3.56 billion by 2029, recording a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is attributable to advancements in immunotherapy, the development of targeted therapies, discoveries related to biomarkers, the application of liquid biopsy, and expanded access programs. Prominent trends for the forecast period encompass patient-centric drug development, the utilization of fast-track and breakthrough designations, innovations in drug delivery systems, collaborative research initiatives, and the incorporation of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

Which Factors And Drivers Are Influencing The Adult Malignant Glioma Therapeutics Market In 2025?

The increasing incidence of brain tumors is projected to boost the growth of the adult malignant glioma therapeutics market. A brain tumor involves an abnormal mass of tissue where the regular cell regulation mechanisms fail to control their unrestrained proliferation and multiplication. Adult malignant glioma is a specific type of brain tumor characterized by cells that grow abnormally and uncontrollably. Treatment for adult malignant glioma addresses these brain tumors through a combination of surgery, radiation therapy, and chemotherapy. For example, in January 2023, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported that the number of brain and nervous system cancer cases rose to 24,810 in 2023, marking a 3.85% increase from 23,890 in 2020. Thus, the rising occurrence of brain tumors is a significant driver for the adult malignant glioma therapeutics market.

What Are The Major Segments Identified In The Adult Malignant Glioma Therapeutics Market?

The adult malignant glioma therapeuticsmarket covered in this report is segmented –

1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types

2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies

3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users

Subsegments:

1) By Glioblastoma Multiforme: Standard Treatments; Experimental Therapies

2) By Anaplastic Astrocytoma: Chemotherapy Options; Targeted Therapies

3) By Anaplastic Oligodendroglioma: Radiation Therapy; Combination Therapies

4) By Anaplastic Oligoastrocytoma: Surgical Interventions; Adjuvant Therapies

5) By Other Types: Rare Gliomas; Emerging Therapies

What Are The Latest Industry Trends Transforming The Adult Malignant Glioma Therapeutics Market?

Leading companies in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to enhance customer service. A small-molecule targeted degrader is a drug that utilizes small molecules to induce the breakdown of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For example, in February 2023, Beactica Therapeutics AB, a precision oncology company from Sweden, was granted orphan drug designation approval by the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). BEA-17 is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, both implicated in the pathogenesis of various cancers, including GBM. The drug operates by degrading LSD1 and CoREST, which results in the reactivation of tumor suppressor genes and the inhibition of cancer cell growth.

Which Major Firms Are Strengthening Their Position In The Adult Malignant Glioma Therapeutics Industry?

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Adult Malignant Glioma Therapeutics Market?

North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Adult Malignant Glioma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp

Browse Through More Reports Similar to the Global Adult Malignant Glioma Therapeutics Market 2025, By The Business Research Company

Digital Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

Leukemia Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795